Literature DB >> 18050131

Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization.

L Arias1, J M Caminal, M Rubio, O Pujol, J Arruga.   

Abstract

PURPOSE: To detect retinal pigment epithelium (RPE) tears in predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) treated with intravitreal bevacizumab injections.
METHODS: Forty consecutive patients with predominantly classic CNV secondary to AMD were treated with 1.25 mg of intravitreal bevacizumab. Patients were evaluated with visual acuity (VA) measured with Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography, and fluorescein angiography.
RESULTS: Three patients developed a RPE tear after the first injection. The first patient had been treated with verteporfin therapy and VA remained unchanged. In the other two cases the CNV was naive and VA improved since the foveal center was not involved by the tear and macular edema was reduced.
CONCLUSIONS: RPE tears can occur following intravitreal bevacizumab injections in patients with predominantly classic CNV although VA is not always affected.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18050131     DOI: 10.1177/112067210701700622

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  8 in total

1.  Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration.

Authors:  Alessandro Mariani; Angeliki Deli; Aude Ambresin; Irmela Mantel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-02       Impact factor: 3.117

2.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

3.  LXA4 protects against blue-light induced retinal degeneration in human A2E-laden RPE cells and Balb-c mice.

Authors:  Tianhua Xie; Jiping Cai; Yong Yao; Chao Sun; Qian Yang; Meili Wu; Zifan Xu; Xiaodong Sun; Xiaolu Wang
Journal:  Ann Transl Med       Date:  2021-08

Review 4.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.

Authors:  Pedro Cuevas; Luis A Outeiriño; Carlos Azanza; Javier Angulo; Guillermo Giménez-Gallego
Journal:  Eur J Med Res       Date:  2012-07-12       Impact factor: 2.175

6.  Retinal pigment epithelial tears following ranibizumab therapy for fibrovascular retinal pigment epithelial detachment due to occult age-related macular degeneration.

Authors:  Małgorzata Figurska
Journal:  Med Sci Monit       Date:  2012-01

7.  Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology.

Authors:  Jonathan A Micieli; Andrew Micieli
Journal:  Mcgill J Med       Date:  2011-06

8.  Spontaneous retinal pigment epithelial tear in type 2 choroidal neovascularization: repair mechanisms following anti-VEGF therapy.

Authors:  Giuseppe Casalino; Vasuki Sivagnanavel; Samir Dowlut; Pearse A Keane; Usha Chakravarthy
Journal:  Int J Retina Vitreous       Date:  2019-01-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.